Effect of natural interferon-β on the growth of melanoma cell lines

Melanoma Research

Volumn 8, Issue 4, 1998, Pages 295-299

  Nagatani, T ^a   Okazawa, H ^a   Kambara, T ^a   Satoh, K ^a   Nishiyama, T ^a   Tokura, H ^a   Yamada, R ^a   Nakajima, H ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Apoptosis; Interferon ; Melanoma; TUNEL methods

Indexed keywords

BETA INTERFERON; BIOLOGICAL RESPONSE MODIFIER; DACARBAZINE; INTERLEUKIN 1; INTERLEUKIN 2; NIMUSTINE; TUMOR NECROSIS FACTOR; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CELL ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL RESPONSE MODIFIERS; CELL DIVISION; DNA REPLICATION; HUMANS; INTERFERON-BETA; MELANOCYTES; MELANOMA; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0031664622     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199808000-00001     Document Type: Article

References (22)

1. von Stamm U, Brocker EB, von Depka Prodzinski M, et al. Effects of systemic interferon-alpha (IFN alpha) on the antigenic phenotype of melanoma metastases. EORTC Melanoma Group Cooperative Study No. 18852. Melanoma Res 1993; 3: 173-180.
2. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993; 3: 291-299.
3. Falkson CI, Falkson G, Falkson HC. Improved results with the addition of interferon alpha2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991; 9: 1403-1408.
4. Vouristo MS. Complete responses and survival after polychemotherapy plus interferon-alpha for patients with metastatic melanoma. Melanoma Res 1996; 6: 331-336.
5. Nagatani T, Ichiyama S, Onuma R, et al. The use of DAV (DTIC, ACNU and VCR) and natural interferon-beta combination therapy in malignant melanoma. Acta Dermatovenereol 1995; 75: 494.
6. Fontaine V, Mahicu M, Content J. Interferon-γ and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways. Melanoma Res 1998; 8: 24-30.
7. Tornusciolo DRZ, Schmidt RE, Roth KA. Simultaneous detection of TdT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections. Biotechniques 1995; 19: 800-805.
8. Wijsman JH, Jonker RR, Keijzer R, et al. A new method to detect apoptosis in paraffin section in situ end-labeling of fragmented DNA. J Histochem Cytochem 1993; 41: 7-12.
9. Creagan ET, Ahmann DL, Frytak S, et al. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 1986; 70: 619-624.
10. Gemlo BT, Palladino MA Jr, Jaffe HS, et al. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864-5867.
11. Taguchi T, Abe S, Nakano K, et al. Synergistic enhancement of the anti-tumor activity of recombinant human TNF-alpha by recombinant human IFN-gamma. Cancer Detect Prev 1988; 12: 1-6.
12. Coates A, Thomson D, McLeod GR, et al. Prognostic value of quality of life score in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29A: 1656-1657.
13. Richards JM, Mehta N, Ramming K, et al. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338-1343.
14. Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Melanoma Res 1994; 4(suppl 1): 21-26.
15. Fierlback G, Ulmer A, Schreiner T, et al. Pharmacodynamics of recombinant IFN-γ during long-term treatment of malignant melanoma. J Interferon Cytokine Res 1996; 16: 777-781.
16. Beli F, Arienti F, Sule-Suso J, et al. Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability Cancer Immunol Immunother 1997; 44: 197-203.
17. Stingl G, Brocker EB, Mertelsmann R, et al. Phase I study to the immunotherapy of metastatic malignant melanoma by cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene. Hum Gene Ther 1996; 7: 551-563.
18. Abdel Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 1997; 80: 401-412.
19. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993; 11: 1969-1977.
20. Tamura T, Ueda S, Yoshida M, et al. Interferon-γ induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun 1996; 229: 21-26.
21. Nguyen H, Lin R, Hiscott J. Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene 1997; 15: 1425-1435.
22. Okazawa H, Nagatani T, Nakajima H. Effects of interferonβ on growth of malignant melanoma cell lines. J Dermatol Sci 1997; 15: 115.